Boston Scientific Goodwill and Intangible Assets 2010-2025 | BSX
Boston Scientific goodwill and intangible assets from 2010 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
- Boston Scientific goodwill and intangible assets for the quarter ending March 31, 2025 were $23.773B, a 16.59% increase year-over-year.
- Boston Scientific goodwill and intangible assets for 2024 were $23.773B, a 16.59% increase from 2023.
- Boston Scientific goodwill and intangible assets for 2023 were $20.39B, a 8.33% increase from 2022.
- Boston Scientific goodwill and intangible assets for 2022 were $18.822B, a 3.94% increase from 2021.
| Boston Scientific Annual Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2024 | $23,773 |
| 2023 | $20,390 |
| 2022 | $18,822 |
| 2021 | $18,109 |
| 2020 | $15,868 |
| 2019 | $18,062 |
| 2018 | $14,283 |
| 2017 | $12,835 |
| 2016 | $12,561 |
| 2015 | $12,667 |
| 2014 | $11,504 |
| 2013 | $11,643 |
| 2012 | $12,262 |
| 2011 | $16,234 |
| 2010 | $16,529 |
| 2009 | $18,603 |
| Boston Scientific Quarterly Goodwill and Intangible Assets (Millions of US $) |
|
|---|---|
| 2024-12-31 | $23,773 |
| 2024-09-30 | $20,787 |
| 2024-06-30 | $19,814 |
| 2024-03-31 | $20,200 |
| 2023-12-31 | $20,390 |
| 2023-09-30 | $19,457 |
| 2023-06-30 | $19,722 |
| 2023-03-31 | $19,329 |
| 2022-12-31 | $18,822 |
| 2022-09-30 | $18,910 |
| 2022-06-30 | $19,232 |
| 2022-03-31 | $19,530 |
| 2021-12-31 | $18,109 |
| 2021-09-30 | $18,047 |
| 2021-06-30 | $16,662 |
| 2021-03-31 | $16,859 |
| 2020-12-31 | $15,868 |
| 2020-09-30 | $16,934 |
| 2020-06-30 | $17,261 |
| 2020-03-31 | $17,491 |
| 2019-12-31 | $18,062 |
| 2019-09-30 | $18,089 |
| 2019-06-30 | $14,937 |
| 2019-03-31 | $14,627 |
| 2018-12-31 | $14,283 |
| 2018-09-30 | $13,885 |
| 2018-06-30 | $13,176 |
| 2018-03-31 | $12,697 |
| 2017-12-31 | $12,835 |
| 2017-09-30 | $12,665 |
| 2017-06-30 | $12,792 |
| 2017-03-31 | $12,423 |
| 2016-12-31 | $12,561 |
| 2016-09-30 | $12,336 |
| 2016-06-30 | $12,405 |
| 2016-03-31 | $12,539 |
| 2015-12-31 | $12,667 |
| 2015-09-30 | $12,696 |
| 2015-06-30 | $11,372 |
| 2015-03-31 | $11,395 |
| 2014-12-31 | $11,504 |
| 2014-09-30 | $11,633 |
| 2014-06-30 | $11,394 |
| 2014-03-31 | $11,499 |
| 2013-12-31 | $11,643 |
| 2013-09-30 | $11,489 |
| 2013-06-30 | $11,579 |
| 2013-03-31 | $11,729 |
| 2012-12-31 | $12,262 |
| 2012-09-30 | $11,878 |
| 2012-06-30 | $12,723 |
| 2012-03-31 | $16,144 |
| 2011-12-31 | $16,234 |
| 2011-09-30 | $16,333 |
| 2011-06-30 | $16,442 |
| 2011-03-31 | $16,554 |
| 2010-12-31 | $16,529 |
| 2010-09-30 | $16,883 |
| 2010-06-30 | $16,998 |
| 2010-03-31 | $17,097 |
| 2009-12-31 | $18,603 |
| 2009-09-30 | $19,287 |
| 2009-06-30 | $19,406 |
| 2009-03-31 | $19,539 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $155.199B | $16.747B |
| Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments - Cardiovascular, Rhythm and Neuro and MedSurg. While Cardiovascular includes Interventional Cardiology and Peripheral Interventions, Rhythm and Neuro comprises Cardiac Rhythm Management, Electrophysiology and Neuromodulation. The MedSurg group comprises 2 sub segments, viz. Endoscopy, Urology and Pelvic Health. Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting stents. Within the CRM segment, the company deals with implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. | |||